Buchang Pharmaceuticals adjusts subsidiary stakes, announces director’s resignation

Shandong Buchang Pharmaceuticals recently announced a series of strategic adjustments, including the proposed waiver of pre-emptive rights for equity in its controlled subsidiary, Shandong Buchang Dingsheng Pharmaceutical Co. The company will forgo its right to acquire 3.00% equity from Zhao Lu, 1.00% from Guo Yubiao, and 1.00% from Cai Yunfei, with total transfer prices of 42,366 yuan, 14,122 yuan, and 14,122 yuan, respectively. Post-transaction, Buchang will hold a 94.00% stake in Dingsheng.

In another move, the company will divest 0.50% of its stake in Shandong Buchang Chuanfang Pharmaceutical Co. to He Tao for 6,875 yuan. Simultaneously, it will waive its pre-emptive rights on additional equity transfers within Chuanfang, including Zhao Lu's 3.00% stake distributed among several transferees for various amounts. These transactions will result in Buchang retaining a 92.5% ownership in Chuanfang.

Additionally, Buchang announced the resignation of Zhao Chao from his positions as non-independent director and member of the Strategy and Investment Committee, effective October 17, 2025, due to personal reasons. Zhao Chao does not hold any company shares, and his departure will not affect the board's operational quorum.